Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels, and median Duration of Response…
Interim data presented at ASCO show early evidence of single agent activity with meaningful reduction of several target lesionsBased on…
Sildenafil Cream-treated patients showed meaningful improvement in the co-primary endpoint assessment that evaluated change from baseline in the Arousal-Sensation Domain…
WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the…
Virtual event to take place on June 14, 2023 at 1:00 pm ET WARRINGTON, Pa., June 05, 2023 (GLOBE NEWSWIRE)…
- No dose limiting toxicities observed with IMM-1-104 up to 320 mg once daily during the Phase 1a dose escalation…
LYON, France and CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic…
SANTA ANA, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (NKGen), a clinical-stage biotechnology company focused on the…
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative…
- Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis is 70% enrolled - WARREN,…